查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1954288

阿片类药物市场分析及预测（至2035年）：类型、产品类型、用途、最终用户、剂型、技术、通路、功能、设备

Opioids Market Analysis and Forecast to 2035: Type, Product, Application, End User, Form, Technology, Distribution Channel, Functionality, Equipment
出版日期: | 出版商: Global Insight Services | 英文 380 Pages | 商品交期: 3-5个工作天内

价格
简介目录

阿片类药物市场预计将从2024年的45亿美元成长到2034年的67亿美元，复合年增长率约为3%。阿片类药物市场涵盖阿片类药物的生产、分销和消费，这些药物主要用于疼痛管理。该市场包括处方阿片类药物（如羟考酮和氢可酮）以及非法阿片类药物（如海洛因）。慢性疼痛病例和外科手术的增加是推动市场成长的主要因素，但同时也面临监管限制和鸦片危机的挑战。抗滥用製剂和替代疼痛疗法的创新正在重塑市场动态，凸显了在有效疼痛管理与降低滥用风险之间取得平衡的必要性。

由于监管环境的变化和对疼痛管理解决方案需求的不断增长，阿片类药物市场正经历动态转型。处方阿片类药物占据市场主导，其中羟考酮和氢可酮因其在慢性疼痛治疗​​中的广泛应用而成为表现最佳的细分市场。Buprenornhine作为部分致效剂，正迅速崛起，成为第二大细分市场，尤其是在成瘾治疗和管理领域。非法阿片类药物市场，特别是Fentanyl等合成鸦片类药物，也经历了显着增长，但同时也面临许多监管和伦理方面的挑战。Fentanyl类似物因其强效作用和在非法市场的普遍存在，已成为该领域一个备受关注的重点。为了在有效缓解疼痛的同时降低滥用风险，人们越来越重视开发抗滥用製剂。非阿片类镇痛替代疗法的创新也推动了市场的发展，为多元化和成长提供了广泛的机会。

市场区隔
类型 天然的、半合成的、合成的
产品 可待因、Fentanyl、美沙酮、氢可酮、羟考酮、氢可酮、Buprenornhine、曲马多
目的 疼痛管理、止咳、止泻、成瘾治疗
最终用户 医院、诊所、居家医疗机构、復健中心
剂型 片剂、胶囊、注射剂、贴片
科技 速释、缓释
通路 医院药局、零售药局、网路药局
功能 镇痛药、麻醉药、镇咳药、止泻药
装置 分配器、输液泵

阿片类药物市场呈现出复杂的市场份额分布格局，这主要受不断演变的定价策略和创新产品的推出所驱动。儘管老牌製药公司占据主导地位，但新参与企业也凭藉新型製剂不断取得进展。策略定价塑造了竞争格局，并且仍然是市场渗透的关键因素。近期推出的产品着重于提高疗效和减少副作用，这反映出市场正朝着以患者为中心的解决方案转变。这种动态环境凸显了策略敏捷性和创新对于维持市场地位的重要性。阿片类药物市场的竞争异常激烈，主要参与者不断相互比较，以保持竞争优势。法规结构对市场动态有显着影响，严格的指导方针影响产品开发和核准流程。北美仍然是领先的市场，这得益于监管政策的发展和旺盛的需求。然而，由于医疗保健投资的增加，亚太地区的成长正在加速。竞争与监管之间的相互作用既带来了挑战，也带来了机会，需要采取策略性方法来应对这个复杂的市场环境。

主要趋势和驱动因素：

由于监管政策的调整、医疗实践的演变以及技术的进步，阿片类药物市场正经历动态变化。其中一个关键趋势是，各国政府和医疗机构越来越重视研发防滥用製剂，以应对全球鸦片危机，减少滥用和成瘾问题。此外，对更安全止痛方案的需求促使人们对非鸦片类镇痛替代方案越来越感兴趣。科技创新发挥着至关重要的作用，数位健康工具和远端医疗的进步正在增强疼痛管理策略。这些技术提供远端监测和个人化治疗方案，与医疗保健领域数位转型的大趋势相契合。此外，人口老化导致老年人慢性疼痛盛行率上升，从而催生了对有效疼痛管理方案的需求，显着推动了市场成长。新兴市场医疗基础设施快速发展，蕴藏着许多机会。投资这些地区的公司有望受益于疼痛管理疗法需求的成长。随着相关人员寻求拓展产品系列併加强市场渗透，策略联盟和伙伴关係也不断增加。阿片类药物市场正在不断发展，重点关注创新和永续实践。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 自然的
    • 半合成
    • 合成
  • 市场规模及预测：依产品划分
    • 可待因
    • Fentanyl
    • 美沙酮
    • 氢可酮
    • 羟考酮
    • 氢可酮
    • Buprenornhine
    • 曲马多
  • 市场规模及预测：依应用领域划分
    • 疼痛管理
    • 咳嗽治疗
    • 腹泻治疗
    • 成瘾治疗
  • 市场规模及预测：依最终用户划分
    • 医院
    • 诊所
    • 居家医疗环境
    • 復健中心
  • 市场规模及预测：依类型
    • 药片
    • 胶囊
    • 注射
    • 修补
  • 市场规模及预测：依技术划分
    • 立即生效
    • 缓释製剂
  • 市场规模及预测：依分销通路划分
    • 医院药房
    • 零售药房
    • 网路药房
  • 市场规模及预测：依功能划分
    • 止痛药
    • 麻醉剂
    • 止咳药
    • 止泻药
  • 市场规模及预测：依设备划分
    • 自动贩卖机
    • 点滴帮浦

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Purdue Pharma
  • Mallinckrodt Pharmaceuticals
  • Endo International
  • Collegium Pharmaceutical
  • Assertio Therapeutics
  • Trevi Therapeutics
  • Egalet Corporation
  • Bio Delivery Sciences International
  • Insys Therapeutics
  • Alkermes
  • Pacira Bio Sciences
  • Zogenix
  • Acel Rx Pharmaceuticals
  • Cara Therapeutics
  • Nektar Therapeutics
  • Heron Therapeutics
  • Titan Pharmaceuticals
  • Elite Pharmaceuticals
  • Pain Therapeutics
  • Durect Corporation

第九章：关于我们

简介目录
Product Code: GIS26464

Opioids Market is anticipated to expand from $4.5 billion in 2024 to $6.7 billion by 2034, growing at a CAGR of approximately 3%. The Opioids Market encompasses the production, distribution, and consumption of opioid drugs, which are primarily used for pain management. This market includes both prescription opioids, such as oxycodone and hydrocodone, and illicit opioids like heroin. The market is driven by rising chronic pain cases and surgical procedures, yet faces challenges from regulatory restrictions and the opioid crisis. Innovations in abuse-deterrent formulations and alternative pain therapies are reshaping market dynamics, emphasizing the need for balance between effective pain management and minimizing abuse potential.

The Opioids Market is experiencing dynamic shifts, driven by evolving regulatory landscapes and increasing demand for pain management solutions. The prescription opioids segment dominates, with oxycodone and hydrocodone being the top-performing sub-segments due to their widespread use in chronic pain treatment. Emerging trends indicate that buprenorphine, a partial agonist, is gaining traction as the second-highest performing sub-segment, especially in addiction treatment and management. The illicit opioids segment, particularly synthetic opioids like fentanyl, is also witnessing significant growth, albeit with considerable regulatory and ethical challenges. Within this segment, fentanyl analogs are emerging as a critical area of concern due to their potency and prevalence in illicit markets. The focus on developing abuse-deterrent formulations is intensifying, as stakeholders seek to balance effective pain management with minimizing abuse potential. Innovations in non-opioid pain relief alternatives are also contributing to market evolution, presenting lucrative opportunities for diversification and growth.

Market Segmentation
TypeNatural, Semi-synthetic, Synthetic
ProductCodeine, Fentanyl, Methadone, Morphine, Oxycodone, Hydrocodone, Buprenorphine, Tramadol
ApplicationPain Management, Cough Treatment, Diarrhea Treatment, De-addiction
End UserHospitals, Clinics, Homecare Settings, Rehabilitation Centers
FormTablets, Capsules, Injectables, Patches
TechnologyImmediate-release, Extended-release
Distribution ChannelHospital Pharmacies, Retail Pharmacies, Online Pharmacies
FunctionalityAnalgesic, Anesthetic, Antitussive, Antidiarrheal
EquipmentDispensers, Infusion Pumps

The opioids market demonstrates a nuanced distribution of market share, influenced by evolving pricing strategies and the introduction of innovative products. Established pharmaceutical companies dominate, yet new entrants are making strides with novel formulations. The competitive landscape is shaped by strategic pricing, which remains a critical factor in market penetration. Recent product launches have focused on enhancing efficacy and reducing side effects, reflecting a shift towards patient-centric solutions. This dynamic environment underscores the importance of strategic agility and innovation in maintaining market relevance. Competition in the opioids market is intense, with major players continuously benchmarking against each other to maintain competitive advantages. Regulatory frameworks significantly impact market dynamics, with stringent guidelines influencing product development and approval processes. North America remains a key market, driven by regulatory advancements and high demand. However, the Asia-Pacific region is witnessing accelerated growth due to increasing healthcare investments. The interplay of competition and regulation presents both challenges and opportunities, necessitating a strategic approach to navigate this complex landscape.

Geographical Overview:

The global opioids market exhibits varied growth dynamics across regions, with distinct emerging opportunities. North America remains dominant, driven by a high prevalence of chronic pain and substantial healthcare expenditure. The region's regulatory landscape, focusing on responsible opioid use, continues to shape market growth. In Europe, the market is stable, supported by a well-established healthcare infrastructure and increasing awareness of pain management solutions. Asia Pacific is a burgeoning hub for market expansion, fueled by rising healthcare needs and improving medical infrastructure. Countries like India and China are at the forefront, driven by large populations and increasing healthcare access. The region's growing focus on modern pain management techniques offers lucrative opportunities for market players. Latin America and the Middle East & Africa are emerging as potential growth pockets. In Latin America, increasing healthcare investments and awareness of pain management are key drivers, while the Middle East & Africa are recognizing the importance of opioids in enhancing quality of life for patients.

The global opioid market is increasingly influenced by tariffs, geopolitical tensions, and supply chain dynamics. Japan and South Korea, traditionally reliant on US pharmaceutical imports, are diversifying supply sources to mitigate tariff impacts. China, amid trade restrictions, is bolstering its domestic pharmaceutical production capabilities, while Taiwan leverages its advanced manufacturing to remain competitive despite geopolitical risks. The parent market for pain management drugs is experiencing moderate growth, driven by aging populations and rising chronic pain incidences. By 2035, market evolution will hinge on regulatory harmonization and innovation in non-addictive analgesics. Middle East conflicts, while primarily affecting energy prices, indirectly pressure global supply chains, increasing production costs and affecting market stability, underscoring the need for strategic resilience and diversification.

Key Trends and Drivers:

The opioids market is experiencing dynamic shifts influenced by regulatory changes, evolving healthcare practices, and technological advancements. A key trend is the increasing emphasis on developing abuse-deterrent formulations. This is in response to the global opioid crisis, as governments and healthcare providers seek to mitigate misuse and addiction. Additionally, there is a growing focus on non-opioid pain management alternatives, driven by the need to provide safer pain relief solutions. Technological innovation plays a pivotal role, with advancements in digital health tools and telemedicine enhancing pain management strategies. These technologies offer remote monitoring and personalized treatment plans, aligning with the broader trend of digital transformation in healthcare. Furthermore, the aging population contributes significantly to market growth, as chronic pain conditions become more prevalent among older adults, necessitating effective pain management solutions. Opportunities abound in emerging markets where healthcare infrastructure is developing rapidly. Companies investing in these regions are likely to benefit from increased demand for pain management therapies. Strategic collaborations and partnerships are also on the rise, as stakeholders aim to broaden their product portfolios and enhance market reach. The opioids market is poised for evolution, with a focus on innovation and sustainable practices.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Application
  • 2.4 Key Market Highlights by End User
  • 2.5 Key Market Highlights by Form
  • 2.6 Key Market Highlights by Technology
  • 2.7 Key Market Highlights by Distribution Channel
  • 2.8 Key Market Highlights by Functionality
  • 2.9 Key Market Highlights by Equipment

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Natural
    • 4.1.2 Semi-synthetic
    • 4.1.3 Synthetic
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Codeine
    • 4.2.2 Fentanyl
    • 4.2.3 Methadone
    • 4.2.4 Morphine
    • 4.2.5 Oxycodone
    • 4.2.6 Hydrocodone
    • 4.2.7 Buprenorphine
    • 4.2.8 Tramadol
  • 4.3 Market Size & Forecast by Application (2020-2035)
    • 4.3.1 Pain Management
    • 4.3.2 Cough Treatment
    • 4.3.3 Diarrhea Treatment
    • 4.3.4 De-addiction
  • 4.4 Market Size & Forecast by End User (2020-2035)
    • 4.4.1 Hospitals
    • 4.4.2 Clinics
    • 4.4.3 Homecare Settings
    • 4.4.4 Rehabilitation Centers
  • 4.5 Market Size & Forecast by Form (2020-2035)
    • 4.5.1 Tablets
    • 4.5.2 Capsules
    • 4.5.3 Injectables
    • 4.5.4 Patches
  • 4.6 Market Size & Forecast by Technology (2020-2035)
    • 4.6.1 Immediate-release
    • 4.6.2 Extended-release
  • 4.7 Market Size & Forecast by Distribution Channel (2020-2035)
    • 4.7.1 Hospital Pharmacies
    • 4.7.2 Retail Pharmacies
    • 4.7.3 Online Pharmacies
  • 4.8 Market Size & Forecast by Functionality (2020-2035)
    • 4.8.1 Analgesic
    • 4.8.2 Anesthetic
    • 4.8.3 Antitussive
    • 4.8.4 Antidiarrheal
  • 4.9 Market Size & Forecast by Equipment (2020-2035)
    • 4.9.1 Dispensers
    • 4.9.2 Infusion Pumps

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Application
      • 5.2.1.4 End User
      • 5.2.1.5 Form
      • 5.2.1.6 Technology
      • 5.2.1.7 Distribution Channel
      • 5.2.1.8 Functionality
      • 5.2.1.9 Equipment
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Application
      • 5.2.2.4 End User
      • 5.2.2.5 Form
      • 5.2.2.6 Technology
      • 5.2.2.7 Distribution Channel
      • 5.2.2.8 Functionality
      • 5.2.2.9 Equipment
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Application
      • 5.2.3.4 End User
      • 5.2.3.5 Form
      • 5.2.3.6 Technology
      • 5.2.3.7 Distribution Channel
      • 5.2.3.8 Functionality
      • 5.2.3.9 Equipment
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Application
      • 5.3.1.4 End User
      • 5.3.1.5 Form
      • 5.3.1.6 Technology
      • 5.3.1.7 Distribution Channel
      • 5.3.1.8 Functionality
      • 5.3.1.9 Equipment
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Application
      • 5.3.2.4 End User
      • 5.3.2.5 Form
      • 5.3.2.6 Technology
      • 5.3.2.7 Distribution Channel
      • 5.3.2.8 Functionality
      • 5.3.2.9 Equipment
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Application
      • 5.3.3.4 End User
      • 5.3.3.5 Form
      • 5.3.3.6 Technology
      • 5.3.3.7 Distribution Channel
      • 5.3.3.8 Functionality
      • 5.3.3.9 Equipment
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Application
      • 5.4.1.4 End User
      • 5.4.1.5 Form
      • 5.4.1.6 Technology
      • 5.4.1.7 Distribution Channel
      • 5.4.1.8 Functionality
      • 5.4.1.9 Equipment
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Application
      • 5.4.2.4 End User
      • 5.4.2.5 Form
      • 5.4.2.6 Technology
      • 5.4.2.7 Distribution Channel
      • 5.4.2.8 Functionality
      • 5.4.2.9 Equipment
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Application
      • 5.4.3.4 End User
      • 5.4.3.5 Form
      • 5.4.3.6 Technology
      • 5.4.3.7 Distribution Channel
      • 5.4.3.8 Functionality
      • 5.4.3.9 Equipment
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Application
      • 5.4.4.4 End User
      • 5.4.4.5 Form
      • 5.4.4.6 Technology
      • 5.4.4.7 Distribution Channel
      • 5.4.4.8 Functionality
      • 5.4.4.9 Equipment
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Application
      • 5.4.5.4 End User
      • 5.4.5.5 Form
      • 5.4.5.6 Technology
      • 5.4.5.7 Distribution Channel
      • 5.4.5.8 Functionality
      • 5.4.5.9 Equipment
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Application
      • 5.4.6.4 End User
      • 5.4.6.5 Form
      • 5.4.6.6 Technology
      • 5.4.6.7 Distribution Channel
      • 5.4.6.8 Functionality
      • 5.4.6.9 Equipment
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Application
      • 5.4.7.4 End User
      • 5.4.7.5 Form
      • 5.4.7.6 Technology
      • 5.4.7.7 Distribution Channel
      • 5.4.7.8 Functionality
      • 5.4.7.9 Equipment
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Application
      • 5.5.1.4 End User
      • 5.5.1.5 Form
      • 5.5.1.6 Technology
      • 5.5.1.7 Distribution Channel
      • 5.5.1.8 Functionality
      • 5.5.1.9 Equipment
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Application
      • 5.5.2.4 End User
      • 5.5.2.5 Form
      • 5.5.2.6 Technology
      • 5.5.2.7 Distribution Channel
      • 5.5.2.8 Functionality
      • 5.5.2.9 Equipment
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Application
      • 5.5.3.4 End User
      • 5.5.3.5 Form
      • 5.5.3.6 Technology
      • 5.5.3.7 Distribution Channel
      • 5.5.3.8 Functionality
      • 5.5.3.9 Equipment
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Application
      • 5.5.4.4 End User
      • 5.5.4.5 Form
      • 5.5.4.6 Technology
      • 5.5.4.7 Distribution Channel
      • 5.5.4.8 Functionality
      • 5.5.4.9 Equipment
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Application
      • 5.5.5.4 End User
      • 5.5.5.5 Form
      • 5.5.5.6 Technology
      • 5.5.5.7 Distribution Channel
      • 5.5.5.8 Functionality
      • 5.5.5.9 Equipment
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Application
      • 5.5.6.4 End User
      • 5.5.6.5 Form
      • 5.5.6.6 Technology
      • 5.5.6.7 Distribution Channel
      • 5.5.6.8 Functionality
      • 5.5.6.9 Equipment
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Application
      • 5.6.1.4 End User
      • 5.6.1.5 Form
      • 5.6.1.6 Technology
      • 5.6.1.7 Distribution Channel
      • 5.6.1.8 Functionality
      • 5.6.1.9 Equipment
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Application
      • 5.6.2.4 End User
      • 5.6.2.5 Form
      • 5.6.2.6 Technology
      • 5.6.2.7 Distribution Channel
      • 5.6.2.8 Functionality
      • 5.6.2.9 Equipment
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Application
      • 5.6.3.4 End User
      • 5.6.3.5 Form
      • 5.6.3.6 Technology
      • 5.6.3.7 Distribution Channel
      • 5.6.3.8 Functionality
      • 5.6.3.9 Equipment
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Application
      • 5.6.4.4 End User
      • 5.6.4.5 Form
      • 5.6.4.6 Technology
      • 5.6.4.7 Distribution Channel
      • 5.6.4.8 Functionality
      • 5.6.4.9 Equipment
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Application
      • 5.6.5.4 End User
      • 5.6.5.5 Form
      • 5.6.5.6 Technology
      • 5.6.5.7 Distribution Channel
      • 5.6.5.8 Functionality
      • 5.6.5.9 Equipment

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Purdue Pharma
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Mallinckrodt Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Endo International
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Collegium Pharmaceutical
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Assertio Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Trevi Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Egalet Corporation
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Bio Delivery Sciences International
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Insys Therapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Alkermes
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Pacira Bio Sciences
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Zogenix
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Acel Rx Pharmaceuticals
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Cara Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Nektar Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Heron Therapeutics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Titan Pharmaceuticals
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Elite Pharmaceuticals
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Pain Therapeutics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Durect Corporation
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us